WO2001056607A1 - Inhibiteurs de l'expression de l'integrine - Google Patents
Inhibiteurs de l'expression de l'integrine Download PDFInfo
- Publication number
- WO2001056607A1 WO2001056607A1 PCT/JP2001/000713 JP0100713W WO0156607A1 WO 2001056607 A1 WO2001056607 A1 WO 2001056607A1 JP 0100713 W JP0100713 W JP 0100713W WO 0156607 A1 WO0156607 A1 WO 0156607A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- added
- mmol
- production example
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to an integrin expression inhibitor. More specifically, an integrin a2j31, a3j31, a5j81, a6 / 31, hivj31, ⁇ 3, or avj35 expression inhibitor, which inhibits integrin expression
- the present invention relates to angiogenesis inhibitors, anticoagulants, anticancer agents, cancer metastasis inhibitors, retinal angiogenesis, diabetic retinopathy, inflammatory diseases, arteriosclerosis, psoriasis, and osteoporosis based therapeutic agents.
- Conventional technology Conventional technology
- Integrin is structurally composed of a heterodimer in which two subunits, integrin and integrin / 3, associate non-covalently. At present, at least 16 types of a chain and 8 types of chains are found. A variety of molecular groups having different ligand specificities are formed by the combination of the a and / 3 chains, and 22 types of integrins are known. Functionally, it is a cell membrane receptor protein for the adhesion molecule of animal cells. It is expressed on the cell membrane and is involved in cell-extracellular matrix (ECM) or cell-cell adhesion. When the cell adhesion molecule binds to integrins, the signaling system in the cell starts to move.
- ECM cell-extracellular matrix
- integrin ⁇ 2j31 is an adhesion molecule consisting of collagen, laminin, etc., platelet aggregation, cancer invasion and metastasis (Masao Hayashi and Yasunori Miyamoto, Protein Nucleic Acid Enzyme, Vol. 44, pp. 130-135) , 1999) and angiogenesis (Donald R. Senger et al, Proc. Natl. Acad. Sci.
- v31 is fibronectin and vitronectin as adhesion molecules.For adhesion to cancer cell substrates, vitronectin and trombosbondin are adhesion molecules.5 is vitronectin as adhesion molecule.
- a 3/31 is fibronectin, collagen, laminin, laminin 5, etc.
- a 5/31 is fibronectin
- a 631 is laminin
- laminin 5, etc. is an adhesion molecule, and it is used for cancer invasion and metastasis. It is known to be involved (Matsuura Nariaki et al., Japanese Clinical 53, 1643-1647, 1995, Ota Ichiro et al., Clinical Pathology, 45, 528-533, 1997).
- WO9550249 discloses an agonist of integrin ⁇ ] 33, but has no suggestion as to its expression inhibitory action.
- the same sulfonamide compounds as those of the present invention are disclosed in JP-A-7-16507-08 and JP-A-8-231505, but there is no description about the integrin expression inhibitory action. No suggestion.
- WO93001182 discloses antitumor agents by the specific tyrosine kinase inhibitory activity of a compound having an indole skeleton, but these are indolylmethylene-2-indolinone compounds, which are different from the present invention. .
- WO964016 discloses an antitumor agent by a specific tyrosine kinase inhibitory activity of a compound having an indole skeleton, but these are 2-indolinone-3-methylene derivatives, which are different from the present invention. different.
- angiogenesis inhibitors anticancer agents, cancer metastasis inhibitors, anticoagulants, arteriosclerosis, psoriasis, retinal angiogenesis, diabetic retinopathy or inflammatory diseases based on integrin expression inhibitory action have been unknown.
- the present invention provides a therapeutic agent for a disease in which an integrin expression inhibitory effect is effective.
- Another object is to provide an integrin expression inhibitor comprising a sulfonamide compound. Disclosure of the invention
- the present inventors have conducted intensive studies and, as a result, have found that a sulfonamide compound having a bicyclic hetero ring has an integrin expression inhibitory action, and completed the present invention.
- Integrin is integrin ⁇ 2, hi3, 5, hi6, av, j31, / 33, ⁇ 4, / 35, hi2j31 ' HI3 j81, a5 ⁇ 1, HI6) 31, ⁇ 1> avj33, or avjS5 1.
- B may have a substituent, a part of the ring may be saturated, C6-C10 aryl or 6- to 10-membered heteroaryl
- K is a single bond,- CH two CH -, or - (CR 4b R 5b) m b -
- R 4b and R 5b are different from one same or different a hydrogen atom, a C1-C4 alkyl group
- m b is an integer of 1 or 2
- R 1 is a hydrogen atom or a C1-C6 alkyl group
- Z is a single bond or -CO-NH-
- R may have a substituent, and a part of the ring is saturated.
- An integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the formula: or a pharmacologically acceptable salt thereof, or a hydrate thereof; Or a pharmaceutically acceptable salt thereof, or an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound according to 3., which is a quinoline, quinoline, or isoquinoline; I a )
- a a ring may have a substituent, a monocyclic or bicyclic aromatic ring
- B a ring may have a substituent, 6-membered cyclic unsaturated hydrocarbon
- a Ca ring optionally having a substituent, a 5- membered hetero ring containing 1 or 2 nitrogen atoms and the R 1 a is hydrogen atom or C1-C6 alkyl group
- Z a is - N (R 2a) - (In the formula, R 2a represents a hydrogen atom or a lower alkyl group.) Or a nitrogen atom.
- W a is a single bond; sulfonamidation compound represented by, or integrin expression inhibitor comprising, as an active Ingredient
- W a is a single bond, with Z a is -NH- There, and sulfonamide compound 5.
- Y a is a carbon atom, if Ku is a pharmacologically acceptable salt thereof or I integrin expression inhibitor as an active ingredient a hydrate thereof; 8.
- B a ring is a benzene or pyridine which may have a substituent 5., 6. or 7.
- the integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound according to 5. or a pharmacologically acceptable salt thereof, or a hydrate thereof, which is NH-; 11.
- a b is a hydrogen atom, a halogen atom, a hydroxyl group, an optionally substituted C1-C4 alkyl group or an alkoxy group with a halogen atom, Shiano group, - (CO) k b NR 2 b R 3 b
- alkenyl or alkynyl group may have a substituent group C2-C4 or an optionally substituted phenyl group or Hue phenoxy group selected from the following group a,
- B b is the following group a An aryl group or a monocyclic heteroaryl group which may have a substituent selected from
- the ring Q b is one or two aromatic ring which may have a nitrogen atom
- the ring M b is a single ring or multiple of C5-C12 unsaturated sharing the ring Q b and double bond means a ring, those ring is a nitrogen atom, an oxygen atom, from 1 selected from sulfur atom to 4 of which may have a hetero atom.
- ring Q b and ring M b if sharing the nitrogen atom A ring ( b and ring M b may have a substituent selected from the following group A): K b is a single bond, or-(CR 4 b R 5 b ) m b - (.
- alkoxy group, Shiano group, - (CO) in n b NR 6 b R 7 b (wherein, R 6b and R 7 b may be substituted by a hydrogen atom or a halogen atom same or different C1- A C4 alkyl group, and n b represents 0 or 1.) or an alkenyl group or an alkynyl group of C2-C4 which may have a substituent], or a nitrogen atom represented by U b and V b are the same or different, and C (D b )-(where D b is as defined above), nitrogen atom, -CH 2- , oxygen atom-or -CO-, Z b is a single bond or -CO-NH-, R lb is a hydrogen atom or a C1-C4 alkyl group,
- Group A a halogen atom, a hydroxyl group, a halogen atom which may C1-C4 be the ⁇ substituted with alkyl group or an alkoxy group, Shiano group, -R 8b R 9b N (NH ) p b - ( wherein, R 8 b Contact And R 9b represents a C1-C4 alkyl group which may be the same or different and may be substituted with a hydrogen atom or a halogen atom, and p b represents 0 or 1.
- R 8b and R sb May form a 5- or 6-membered ring together with the nitrogen atom to which it is bonded, and the ring may further contain a nitrogen atom, an oxygen atom or a sulfur atom, and may have a substituent.
- Sulfonamide-containing heterocyclic compound represented by, or integrin expression inhibitor and its pharmacologically acceptable salts or active ingredient a hydrate thereof,;. 1 2 U b and V b is C ( D b )-(wherein D b is as defined above), or a nitrogen atom, the sulfonamide-containing heterocyclic compound according to 11. Or a pharmacologically acceptable salt thereof, or a salt thereof.
- an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide-containing heterocyclic compound described in 1 or 2, or a pharmacologically acceptable salt thereof, or a hydrate thereof; 14.4 T b , U b , 11.
- the sulfonamide-containing heterocyclic compound or the pharmaceutically acceptable salt thereof according to any one of 11. to 13., wherein at least one of V b , X b and Y b is a nitrogen atom. or integrin expression inhibitor a hydrate thereof as an active Ingredient,; 1 5.
- a b is a halogen atom, a halogen atom with optionally substituted C1-C4 alkyl group or an alkoxy group, Shiano group, - ( CO) r b NR 12b R 13 (wherein, R 12b and R 13b are the same or different and each represents a C1-C4 alkyl group optionally substituted with a hydrogen atom or a halogen atom, and r b is 0 or Means 1.) or has a substituent 11.
- a sulfonamide-containing heterocyclic compound according to any one of 1 to 1 which is a C2-C4 alkenyl group or an alkynyl group, or a pharmaceutically acceptable salt thereof, or a water thereof.
- integrin expression inhibitor of hydrate as an active ingredient; 1 6.
- one T b, W b or Y b The sulfonamide-containing heterocyclic compound according to any one of the above, wherein only one is a nitrogen atom, or a pharmacologically acceptable salt thereof, or a hydrate thereof is used as the active ingredient Integrin expression inhibitor; 1 8. Integrin 5.
- integulin is integrin ⁇ 2/31, a 3 j31, ⁇ 5 j31, a 6 ⁇ 1, ⁇ 1, ⁇ 3, or ⁇
- the sulfonamide compound according to any one of the above, a pharmacologically acceptable salt thereof, or a hydrate thereof is effective. It relates to 1) a therapeutic agent for arteriosclerosis, psoriasis, or osteoporosis, or 2) an anticoagulant, based on the inhibitory action of integrin expression as a component.
- the present invention relates to administering a compound represented by any of the formulas (I), (la) and (lb), a pharmacologically acceptable salt thereof, or a hydrate thereof to a patient in a pharmacologically effective amount.
- the present invention provides a method for preventing, treating, or improving a disease for which the inhibition of integrin expression is effective by administering the compound to a human.
- the present invention relates to a compound represented by any of the formulas (1), (la) and (lb), or a pharmacologically acceptable salt thereof, or a hydrate thereof, which inhibits the expression of integrin.
- a compound represented by any of the formulas (1), (la) and (lb) or a pharmacologically acceptable salt thereof, or a hydrate thereof, which inhibits the expression of integrin.
- diseases for which inhibition of integrin expression is effective include arteriosclerosis, psoriasis, cancer, osteoporosis, retinal angiogenesis, diabetic retinopathy or inflammatory disease.
- the preventive, therapeutic or ameliorating agent for a disease for which inhibition of integrin expression is effective includes arteriosclerosis, psoriasis, cancer, osteoporosis, retinal neovascularization, diabetic retinopathy or inflammatory disease. Contains therapeutic agents, anticoagulants, cancer metastasis inhibitors, and angiogenesis inhibitors.
- a C6-C10 aryl ring or a 6- to 10-membered heteroaryl ring, which may have a substituent and may be partially saturated in B and R, is a carbon atom.
- Can be The aromatic ring may have 1 to 3 substituents, and when there are a plurality of substituents, they may be the same or different.
- substituents examples include an amino group, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a nitro group, a mercapto group, a cyano group, a lower alkylthio group which may be substituted with a lower alkyl group or a lower cycloalkyl group, A a -b a (where a a is a single bond,-(CH 2 ) k a- , -0- (CH 2 ) k a- , -S- (CH 2 ) k a- Or -N (R 3a )-(CH 2 ) k a- , k a is an integer of 1 to 5, R 3a is a hydrogen atom or a lower alkyl group, and b a is -CH 2 -d a ( In the formula, da represents an amino group, a halogen group, a hydroxyl group, a lower alkylthio group, a
- a a has the same meaning as described above, e a represents —S (O) — or —S (O) 2 —, and f a represents a lower alkyl group or a lower alkoxy group Replace with Or unprotected amino group, a lower alkyl group, triflate Ruo Russia methyl group, - (CH 2) m a -b a or - N (R 4a) - ( CH 2) m a -b a ( wherein, b a have the same meanings as defined above, the R 4a is a hydrogen atom or a lower alkyl group, m group a is represented by 'means an integer of 1 to 5), wherein one a a _g a - h a Wherein a a represents the same meaning as described above, g a represents -C (O)-or -C (S)-, and ha represents an amino group which
- a "may have a substituent, a monocyclic or bicyclic aromatic ring” refers to the a ring with an aromatic hydrocarbon or a nitrogen atom, SansoHara An aromatic hetero ring containing at least one of a substituent and a sulfur atom, and the ring may have 1 to 3 substituents.
- a Examples of the main aromatic ring contained in the a ring include pyrrole, pyrazol, imidazole, thiophene, furan, thiazole, oxazole, benzene, pyridine, pyrimidine, pyrazine, pyrazine, naphthalene, quinoline, isoquinoline, phthalazine, Examples include naphthyridine, quinoxaline, quinazoline, cinnoline, indole, isoindole, indolizine, indazole, benzofuran, benzothiophene, benzoxazole, benzimidazole, benzopyrazole, and benzothiazol.
- the aromatic ring may have 1 to 3 substituents, and when there are a plurality of substituents, they may be the same or different.
- substituents include an amino group, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a nitro group, a mercapto group, a cyano group, a lower alkylthio group which may be substituted with a lower alkyl group or a lower cycloalkyl group, Halogen group, formula — a a — b a [where a a is a single bond,-(CH 2 ) k a- , -0- (CH 2 ) k a- , -S- (CH 2 ) k a- Or -N (R 3 a )-(CH 2 ) k a- , k a is an integer of 1 to 5, R 3 a is a hydrogen atom or a lower alkyl group, and b a is
- the R 4a is a hydrogen atom or a lower alkyl group
- m group a is represented by 'means an integer of 1 to 5), wherein one a a _ g a -h a [wherein, a a Has the same meaning as described above, g a represents -C (O)-or -C (S)-, and h a represents an amino group optionally substituted with a lower alkyl group, a hydroxyl group, a lower alkyl group, a lower alkoxy group.
- R 5a is a hydrogen atom or a lower alkyl group
- n a is 1 to 5
- ⁇ a represents a hydrogen atom, a lower alkoxy group or f a (where f a has the same meaning as described above)], a group represented by the formula-& 3- !
- these alkyl groups may combine to form a 5- or 6-membered ring.
- a a ring is a nitrogen-containing hetero ring having a hydroxyl group or a mercapto group, these groups form a oxo or thioxo group by forming a resonance structure. It may be.
- Means of B a ring may have a substituent, heterocyclic and 6-membered cyclic unsaturated hydrocarbon or nitrogen atom as heteroatoms is to one containing unsaturated 6-membered” is a part May be hydrogenated, benzene or pyridine, and may have one or two substituents on the ring, and when there are two substituents, they may be the same or different Good.
- ring C a The “optionally substituted, 5-membered heterocyclic ring containing one or two nitrogen atoms” represented by ring C a refers to pyrrole, pyrazole, which may be partially hydrogenated And imidazole, which may have one or two substituents on the ring, and when there are two substituents, they may be the same or different.
- the B a ring and C a ring substituents which may have, for example, a halogen group, Shiano group, a lower alkyl group, a lower alkoxy group, a hydroxyl group, Okiso group, the formula - C (0) -r a (
- 1 " a represents a hydrogen atom, an amino group optionally substituted with a lower alkyl group, a lower alkyl group, a lower alkoxy group or a hydroxyl group), an amino group optionally substituted with a lower alkyl group, Trifluoromethyl groups and the like can be mentioned.
- preferred groups include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, and the like.
- the most preferred groups are a methyl group and an ethyl group. Examples include a tyl group, an n-propyl group, and an isopropyl group.
- the lower cycloalkyl group in the definition of A a ring substituents which may have, there can be mentioned a cyclopropyl group, a cyclopentyl group, etc. cyclohexyl group.
- a a ring, the B a ring and C a lower an alkoxy group ring in the definition of the substituent which may have a methoxy group, an ethoxy group, n- propoxy group, isopropoxy group, n- butoxy group And a lower alkoxy group derived from the above lower alkyl group such as an isobutoxy group and a tert-butoxy group.
- the most preferred groups include a methoxy group and an ethoxy group.
- the halogen atom include a fluorine atom, a chlorine atom, and a bromine atom.
- particularly preferred compounds include
- the sulfonamide derivative represented by the general formula ( Ia ) may form a salt with an acid or a base in some cases.
- the present invention also includes a salt of the compound ( Ia ).
- salts with acids include inorganic salts such as hydrochloride, hydrobromide, and sulfate, acetic acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid, p — Salts with organic acids such as toluenesulfonic acid.
- the salt with a base examples include salts with inorganic salts such as sodium salt, potassium salt, and calcium salt, and salts with organic bases such as triethylamine, arginine, and lysine.
- the “aromatic ring optionally having one or two nitrogen atoms” that is meant by ring Q b is an aromatic hydrocarbon or a six-membered aromatic containing one or two nitrogen atoms. Heterocycle. To illustrate the major aromatic ring contained in the ring Q b, benzene, pyridine, pyrimidine, pyrazine, pyridazine, and the like.
- a ring M means ⁇ a C5-C12 unsaturated monocyclic or bicyclic ring, wherein the ring has 1 to 4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. and may be.
- the, heptene be monocyclic or multi-cyclic unsaturated sharing the ring Q b and double bond, hexene benzene, naphthoquinone evening aromatic hydrocarbons Ren like, cyclopentene, cyclohexane, cycloheptane Unsaturated hydrocarbons such as cyclooctene, cyclopentene, cycloheptane, cycloheptagene, tetrahydropyridine, pyrrole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyrazole, imidazole, triazole, pyridine , Pyrimidine, pyrazine, pyridazine, triazine, indole, isoindole, quinoline, isoki Phosphorus, Indazorijin, naphthyridine, benzofuran, benzopyran, benzothioph
- Ring Q b and ring M b may share one nitrogen atom.”
- R 15b, G lb, and the C1-C4 alkyl group in G 2 b and A may be substituted by a halogen atom in the group Cl @ - C4 alkyl group, a linear or branched alkyl of 1-4 carbon atoms Group, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl.
- a halogen atom means that these alkyl groups may be substituted with a halogen atom selected from a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- Preferred examples are monofluoromethyl, difluoromethyl, trifluoromethyl, 1- or 2-monofluoroethyl, 1,2-difluoroethyl, 1,1,2,2 , 2-pentylfluoroethyl group and the like.
- the C1-C4 alkoxy group in the C1-C4 alkoxy group which may be substituted with a halogen atom in the groups A b , D b and A is a straight-chain or branched alkoxy having 1 to 4 carbon atoms.
- Groups for example, methoxy, ethoxy, n- propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy.
- halogen atom optionally substituted by a halogen atom
- alkoxy groups are a fluorine atom, a chlorine atom, a bromine It means that it may be substituted with a halogen atom selected from an atom and an iodine atom.
- a halogen atom selected from an atom and an iodine atom.
- Preferred of those examples are monofluoromethoxy, difluoromethoxy, trifluoromethoxy, 1- or 2-monofluoroethoxy, 1,2-difluoroethoxy, 1,1,2,2, Examples thereof include a 2-phenylfluoroethoxy group.
- the C2-C4 alkenyl or alkynyl group can be seen in A b and D b means an alkenyl group or an alkynyl group having 2 to 4 carbon atoms, vinyl group, Ariru group, 2- or 3- Butenyl, 1,3-butenyl, ethynyl, 2-propynyl, 2-methylethynyl, 2- or 3-butynyl and the like.
- the Ariru group found at B b and group A means an aromatic hydrocarbon, phenyl group, and a naphthyl group.
- a heteroaryl group is a monocyclic or bicyclic ring containing one or more nitrogen, oxygen, and sulfur atoms.
- Examples include a pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furyl, and phenyl group.
- oxazolyl group isoxazolyl group, thiazolyl group, isothiazolyl group, thiadiazolyl group, pyridyl group, pyrimidyl group, virazyl group, indolyl group, indolizinyl group, benzimidazolyl group, benzothiazolyl group, benzoxazolyl group, quinolinyl group, Examples include an isoquinolinyl group, a quinazolinyl group, and a phthalazinyl group.
- R 8 b, "R 8 b and R 9 b seen in R 9 b may form a connexion 5 or 6 membered type ring such together with the nitrogen atom to which they are attached the ring further nitrogen atom may contain an oxygen atom or a sulfur atom, "it refers to connexion pyrrolidinyl groups together with the nitrogen atom to which R 8 b and R 3 b is engaged binding, piperidinyl group, Moruho Reno Group, thiomorpholino group, piperazinyl group and the like.
- An alkyl group or a phenylsulfonylamino group optionally having a substituent or a C1-C4 alkyl group optionally substituted with a C1-C4 alkyl group means the same alkyl group as described above,
- the group includes a methylene group, an ethylene group, a propylene group, a butylene group, a methylmethylene group, a 1- or 2-methylethylene group, a 1-, 2- or 3-methylpropylene group, a dimethylmethylene group, and the like. it can.
- ⁇ means a C1-C8 alkanoyl group and a formyl group, an acetyl group, a propionyl group, a butyryl group, an isoptyryl group, a valeryl group, a benzoyl group and the like.
- the protecting group in the carboxy group which may have a protecting group and the protecting group for the carboxy group in R 16b may be any group known as a protecting group for a carboxy group in ordinary organic synthesis.
- examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a t-butyl group, a methoxymethyl group, a 2,2,2-trichloromethyl group, and a pivaloyloxymethyl group. And a benzyl group.
- the substituent in "may have a substituent (s)" refers to the above-mentioned halogen atom, a C1-C4 alkyl group or an alkoxy group optionally substituted with a halogen atom, a hydroxyl group, a hydroxy C1-C4
- the sulfonamide-containing heterocyclic compound represented by the above general formula ( Ib ) may form a salt with an acid or a base in some cases.
- the present invention also includes a salt of compound (I b ).
- salts with acids include inorganic salts such as hydrochloride, hydrobromide, and sulfate, acetic acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid, and the like.
- Examples thereof include salts with an organic acid such as p-toluenesulfonic acid.
- the salt with a base include inorganic salts such as a sodium salt, a potassium salt, and a calcium salt, and salts with an organic base such as triethylamine, arginine, and lysine.
- the present invention also includes a compound that undergoes metabolism such as oxidation, reduction, or hydrolysis in vivo to produce the compound of the present invention.
- Compound ( Ia ) according to the present invention can be produced by various methods.
- Japanese Patent Application Laid-Open Nos. 7-165708 and 8-231505 disclose some of them specifically.
- the compound ( Ia ) of the present invention can be produced by various methods. Among them, representative methods are as follows, for example.
- the ring Ba a may have a protected or unprotected substituent, and is a 6-membered unsaturated hydrocarbon or unsaturated containing one nitrogen atom as a hetero atom.
- the heterocyclic 6-membered, C a a ring means heterocycle may have a protected or unprotected substituent, a nitrogen atom to the 1 or 2 containing 5-membered, X a, Y a and Z a may be prepared Ri by the reacting the compound represented by the same means showing a) above.
- Examples of the reactive derivative of sulfonic acid (IP) include reactive derivatives that are commonly used, such as sulfonyl halide, sulfonic anhydride, and N-sulfonylimidazolide.
- a particularly preferred example is a sulfonyl halide.
- the solvent used in the reaction is not particularly limited, but is preferably one that dissolves the starting materials and does not easily react with them, such as pyridine, tetrahydrofuran, dioxane, benzene, ethyl ether, dichloromethane, dimethylformamide, or a mixture thereof.
- a mixed solvent of two or more kinds can be used.
- a suitable deoxidizing agent In the case where an acid is liberated with the progress of the reaction as in the case of using a sulfonyl halide in this reaction, it is preferable to carry out the reaction in the presence of a suitable deoxidizing agent.
- a basic solvent is particularly preferred. When a neutral solvent is used, a basic substance such as alkali carbonate or organic tertiary amine may be added. Of course, the solvents that can be used are not limited to those listed here.
- this reaction proceeds at room temperature, but may be cooled or heated as necessary.
- the reaction time is usually from 10 minutes to 20 hours, but is arbitrarily selected depending on the type of the starting compound and the reaction temperature.
- a normal deprotection method such as acid treatment, alkali treatment, or catalytic reduction may be used if necessary.
- acid treatment alkali treatment
- catalytic reduction it is possible to obtain a sulfonamide derivative or a sulfonate derivative ( Ia ) having a free hydroxyl group or amino group.
- halogenating agent a compound I Table in.
- the halogenating agent include N-chlorosuccinimide, N-bromosuccinic imide, 1,3-dibromo-1,5-dimethylhydantoin, N-bromoacetamide, chlorine, and bromine.
- the solvent used in the reaction is not particularly limited, but usually an alkyl chloride compound such as dichloromethane, chloroform, carbon tetrachloride or the like, or an aromatic chloride such as chlorobenzene or dichlorobenzene is used, but dimethylformamide or dioxane is used. Water-soluble solvents such as pyridine, acetonitrile and the like can also be used.
- the reaction temperature varies depending on the type of the halogenating agent and the substrate, but is usually between -50 and 100.
- the amino or hydroxyl group When the amino or hydroxyl group is protected in the obtained product, it has a free hydroxyl or amino group by performing a normal deprotection method such as acid treatment, alkali treatment or catalytic reduction, if desired. It is possible to obtain a sulfonamide derivative or a sulfonate derivative ( Ia ).
- E a means a substituent convertible into Shiano group by dehydration
- compound represented by the To It can be produced by reacting with a dehydrating agent.
- substituents that can be converted to a cyano group by dehydration include (hydroxyimino) methyl group, carbamoyl group and the like.
- oxime or acid amide from the starting aldehyde or carboxylic acid and react it with a dehydrating agent without isolation.
- a dehydrating agent include methods generally used for synthesizing nitrile, such as acetic anhydride, thionyl chloride, phosphorus oxychloride, selenium dioxide, and 1,3-dicyclohexylcarbodiimide.
- the solvent used in the reaction is not particularly limited, but is preferably one that dissolves the starting materials and does not easily react with them, for example, pyridine, ethyl ether, benzene, dimethylformamide, carbon tetrachloride, acetonitrile, tetrahydrofuran, or a mixture thereof. A mixture of two or more selected solvents can be used.
- the reaction temperature varies depending on the type of the dehydrating agent and the substrate, but is usually between ⁇ 50 T: and 150.
- the amino or hydroxyl group When the amino or hydroxyl group is protected in the obtained product, it has a free hydroxyl or amino group by performing a normal deprotection method such as acid treatment, alkali treatment or catalytic reduction, if desired. It is possible to obtain a sulfonamide derivative or a sulfonate derivative ( Ia ).
- the Aba ring has a substituent convertible to an amino group by reduction, and may further have a protected or unprotected substituent, a monocyclic or bicyclic ring means a formula aromatic ring production, B a a ring, C a a ring, W a, X a, by the Y a and Z a are reacted with a reducing agent a compound represented by same meaning indicating the taste) and the can do.
- Substituents that can be converted to amino groups by reduction include nitro and nitro Group, hydroxyamino group and azo group.
- nitro group reduction method For the reduction, a commonly used nitro group reduction method can be used. Preferred examples include catalytic reduction using a catalyst such as palladium-carbon or platinum oxide, and reduction with zinc, iron or tin and an acid. Can be mentioned. Catalytic reduction can be usually performed in an organic solvent such as methanol, tetrahydrofuran, dimethylformamide or the like under normal pressure or under pressure.
- a sulfonamide derivative or a sulfonate ester having a free hydroxyl group can be obtained by performing a normal deprotection method such as acid treatment, alkali treatment, or catalytic reduction, if desired. It is possible to obtain the derivative ( Ia ).
- a c a ring having a leaving group in the ring or on a substituent, is also protected in the other may have a substituent group unprotected, monocyclic or bicyclic refers to cyclic aromatic ring, B a a ring, C a a ring, W a, the XY a and Z a are prepared by reacting a nucleophile of the compound represented by the same means showing a) and the Can be.
- the leaving group include a halogen group, a methanesulfonyloxy group, and a p-toluenesulfonyloxy group.
- the nucleophile include amines, alcohols, and thiols.
- the reaction may be carried out in the form of a salt with an alkali metal.
- the solvent used for the reaction is not particularly limited, but is preferably a solvent that dissolves the starting materials and does not easily react with them, for example, tetrahydrofuran, dioxane, dimethylformamide, water and the like.
- the reaction temperature varies depending on the type of substrate, but is usually between 150 ° C and 150 ° C.
- the amino or hydroxyl group is protected in the obtained product, it has a free hydroxyl or amino group by performing a normal deprotection method such as acid treatment, alkali treatment or catalytic reduction, if desired. It is possible to obtain a sulfonamide derivative or a sulfonate derivative ( Ia ).
- the starting compound (IP) and its reactive derivatives include known compounds and novel compounds.
- a new compound it can be produced by applying a known method for synthesizing a known compound or by combining them.
- a novel sulfonylic mouth lid is Chem. Ber., ⁇ Q, 841 (1957), J. Med. Chem., 307 (1963), J. Chem. Soc. (C), 1968. 1265, Chem. Lett. ., 1992. 1483, J. Am. Chem. Soc, ⁇ 2, 1837 (1937), J. Med. Chem., 2 ⁇ , 1376 (1980), J. Am. Chem. Soc "7Q, 375 (1948) , J. Am. Chem. Soc, IS, 2171 (1956).
- the starting compound (m a ) includes known compounds and novel compounds.
- H—X a— represents an amino group H 2 N—
- the nitro compound is reduced by a generally used reduction method of a nitro group to form an H 2 N form.
- Preferred examples of the reduction method include catalytic reduction using palladium-carbon as a catalyst and reduction using zinc dust-hydrochloric acid.
- the catalytic reduction can be usually performed in an organic solvent such as methanol, tetrahydrofuran, dimethylformamide or the like under normal pressure or under pressure.
- the HO form ( ⁇ ⁇ can be obtained by diazotizing the above amino form and then hydrolyzing it.
- the starting compound is a novel compound
- it can be produced by applying a known method for synthesizing a known compound or by combining them.
- New compounds are applied by methods described in Can. J. Chem., 42, 1235 (1964), Chem. Abst., 8855f (1963), Tetrahedron Lett., 2Q, 2129 (1989), etc. Then, for example, it is possible to manufacture by the following route
- Q a represents the same or different substituent
- G a represents a halogen group
- t a is an integer of 0 to 2.
- Q a , G a and t a have the same meaning as described above, and DP PA means diphenylphosphoryl azide.
- Q a , G a and t a have the same meanings as described above, and DDQ means 2,3-dichloro-5,6-dicyanone-1,4-benzquinone.
- the compound (I b ) of the present invention can be produced by various methods.
- the typical method is as follows.
- Examples of the reactive derivative of sulfonic acid (V b ) include commonly used reactive derivatives such as, for example, sulfonyl halide, sulfonic anhydride, and N-sulfonylimidazolide.
- a preferred example is sulfonyl halide.
- the solvent used in the reaction is not particularly limited, but is preferably a solvent that dissolves the raw materials and does not easily react with them, such as pyridine, tetrahydrofuran, dioxane, benzene, ethyl ether, dichloromethane, dimethylformamide, or A mixed solvent of two or more selected solvents may be used.
- the reaction is preferably carried out in the presence of an appropriate deoxidizing agent.
- a basic solvent is particularly preferred.
- a basic substance such as alkali carbonate or organic tertiary amine may be added.
- the solvents that can be used are not limited to those listed here.
- this reaction proceeds at room temperature, but may be cooled or heated as necessary.
- the reaction time is usually 10 minutes to 20 hours, It is arbitrarily selected depending on the reaction temperature.
- the amino or hydroxyl group When the amino or hydroxyl group is protected in the obtained product, it has a free hydroxyl or amino group by performing a normal deprotection method such as acid treatment, alkali treatment, or catalytic reduction, if desired.
- sulfonamide derivative (VII b) can be obtained.
- L b represents a chlorine atom or a bromine atom
- R 17b represents a C1-C4 alkyl group or a benzyl group
- a b , B b , T b , U h , V b , W b , X b and T b are the same as defined above.
- It can be produced by reacting a compound isocyanate represented by the formula (Vin b ) with a sulfonamide compound represented by the formula (IX b ).
- the reaction is generally carried out in water or in a water-miscible non-reactive solvent such as tetrahydrofuran or acetone, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium hydroxide.
- a water-miscible non-reactive solvent such as tetrahydrofuran or acetone
- sodium hydroxide potassium hydroxide
- lithium hydroxide sodium hydroxide
- the reaction is performed in the presence of a base such as toxide or sodium hydride.
- the reaction is carried out at 0 ° C to 100 ° C.
- the preferred temperature is about 20 to 30 ° C.
- reaction formula (XI b) represented by Amin and formula (IX b) sulfonamide of formula (XIII b) in are expressions obtained by reacting a haloformate represented represented (XII b) This is a method of reacting the lubamate represented by
- a non-reactive solvent, potassium carbonate reaction with a haloformate of formula sulfonamides of formula represented by (IX b) (XIII b) is acetone, tetrahydrofuran, and methyl E chill ketone, sodium carbonate, water Perform in the presence of an acid scavenger such as potassium oxide or sodium hydroxide. The reaction is carried out at a temperature of about 30 ° C to the reflux temperature.
- the formula the reaction of (XII b) represented by the force Rubameto in and the Amin of the formula (XI b) is Jiokisan, toluene, high-boiling solvent, inert such as diglyme, from about 5 0 To the reflux temperature.
- Amin compound represented by the raw material is expression of sulfonamide or Suruhoniruurea containing heterocyclic compound of the present invention compounds (VI b) or (XI b) can be prepared by combining viewed known methods .
- quinoline and isoquinoline derivatives can be produced by the following production steps.
- R 18b represents the above, and R 13b represents a C1-C4 alkyl group.
- R 18 b, the E 2b is the, R 2QB and R 21 b is hydrogen atom or C1-C4 alkyl le group
- R 22 b is have C1-C4 alkoxy group, a substituent A phenoxy group or a phenyl group, a cyano group, a mono- or di-amino group which may be substituted with a C1-C4 alkyl group
- E 3b a hydrogen atom, a halogen atom, a C1-C4 alkoxy group, a substituent A phenyl or phenyl group, a cyano group, or an amino group optionally substituted with a mono- or di-C1-C4 alkyl group.
- the dosage is not particularly limited and varies depending on the symptoms, age, sex, weight, sensitivity difference, administration method, administration timing, administration interval, characteristics of pharmaceutical preparation, preparation, type, type of active ingredient, etc. of the patient. However, it is usually 10 to 6000 mg , preferably about 50 to 4000 mg, more preferably 100 to 3000 mg per day for an adult, which is usually administered once to three times a day.
- excipients and, if necessary, binders, disintegrants, lubricants, coloring agents, flavoring agents, etc. are added to the active ingredient, and then tablets, coated tablets, Granules, fine granules, powders, capsules, etc.
- Excipients include, for example, lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose, silicon dioxide, and the like.
- Binders include, for example, polyvinyl alcohol, ethyl cellulose, methyl cellulose, acacia, hydroxypropyl cellulose, Hydroxypropyl methylcellulose, etc., as lubricants, for example, magnesium stearate, talc, silica, etc., are permitted to be added to pharmaceuticals as coloring agents, while cocoa powder is used as a flavoring agent.
- lubricants for example, magnesium stearate, talc, silica, etc.
- Heart muscle, aromatic acid, heart oil, dragon brain, cinnamon powder, etc. are used. These tablets and granules are sugar-coated, gelatin-coated, etc. You can of course do it.
- suspending agent examples include methylcellulose, polysorbate 80, hydroxycellulose, gum arabic, tragacanth powder, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, and the like.
- solubilizer examples include polyoxyethylene hydrogenated castor oil, polysorbate 80, nicotinamide, polyoxyethylene sorbin monolaurate, macrogol, and castor oil fatty acid ethyl ester.
- examples of the stabilizer include sodium sulfite and sodium metasulfite
- examples of the preservative include methyl paraoxybenzoate, ethyl parahydroxybenzoate, sorbic acid, phenol, cresol, and chlorocresol. it can.
- FIG. 1 shows the results of measuring the integrin expression level of compound A (untreated and 0.05 g / ml) on human umbilical vein vascular endothelial cells 48 hours after inoculation.
- the lower T / C shows the effect of Compound A on no treatment in%.
- Figure 2 shows the effect of compound A (0.05Mg / ml) on integrin expression after 48 hours against human colorectal cancer cell line (HCT116-C9): T / C (%) was.
- FIG 3 shows the high concentrations of compound A (0.5,
- Integrin expression inhibitory action after 48 hours at 5Mg / ml The effect of Compound A on no treatment was indicated by T / C (%.).
- Figure 4 shows each compound (0.5 g / ml) against human umbilical vein vascular endothelial cells (HUVEC). Inhibition of expression of integrin 2 at 48 hours after: The ratio of expression amount to no treatment (%) was shown. (The name of each compound is indicated by the number of Synthesis Example.) The effects of this compound will be shown below by pharmacological experiment examples.
- the compound A in the pharmacological experiment example refers to the compound obtained in Synthesis Example 1.
- Example 1 Inhibition of intedalin expression on human umbilical vein vascular endothelial cells (HUVEC)
- Compound A suppressed the expression of integrin 2, 3, a5, ⁇ 6, av, ⁇ 1, ⁇ 3, and i35 on the cell surface at a concentration of 0.05 g / ml. .
- Example 2 Integrin Expression Inhibiting Effect on Human Colorectal Cancer Cell Line (HCT116-C9) The integrin expression inhibiting effect of compound A on the above cells was examined in the same manner as in Example 1.
- Compound A inhibited the expression of integrin ⁇ 2, hi3, a5, a6, ⁇ 1, 34 at concentrations of 0.05 g / ml and 0.5 g / ml.
- Example 3 Integrin expression inhibitory effect on human normal fibroblast cell line (WI38) In the same manner as in Example 1, the integrin expression inhibitory effect of compound II on the above cells was examined.
- the degree of inhibition of neovascularization observed when a rat aorta fragment was cultured in collagen was defined as angiogenesis inhibitory activity. That is, the aorta extracted from a Sprague-Dawley female rat (10 to 12 weeks of age) is carefully washed with Hank's solution to remove surrounding fat tissues. After incising the aorta to make a 2 mm square section, place it in a 24-well plate with the endothelial cell surface facing up. Next, 5001 neutralized evening I collagen (Cell Matrix Type IA: Nitta Gelatin) is poured into each well, and the gel is allowed to harden at room temperature for about 20 minutes in a clean bench.
- Cell Matrix Type IA Nitta Gelatin
- MCDB131 medium 500 (Chlorella Kogyo) were added after confirming that the gel was solid pine and lower cultured at 37 in C0 2 incubator (5% C0 2). On the next day, exchange the medium with 500 1 MCDB131 medium containing the test compound and continue the culture. Three days later, the medium was replaced again with 500 1 MCDB131 medium containing the test compound, and the number of capillaries formed around the aorta was counted under a microscope seven days after the start of the addition of the test compound. The test compound-containing solution was prepared in a three-fold dilution series with a maximum concentration of 10 g / ml.
- the inhibition rate was calculated from the following formula, and the 50% inhibitory concentration (IC 5 value) of each test compound was determined.
- Inhibition rate (%) (C-T) / C X 100
- T number of capillaries when compound is added
- Compounds related to the present invention is IC 5 of 0.05 to 3 g / ml. The value was shown.
- the above activity was evaluated using a method that was partially modified from the mouse air sac method (Sakamoto et al., Cancer Res., 1, 55-57, 1986). That is, the Millipore Ring (Nippon Millipore) was sealed with a 0.22 m membrane filter (HAWPO: Nippon Millipore) to create a chamber. Seven human colorectal cancer cell lines (WiDr) suspended in a phosphate buffer in this chamber were filled with lxlO. Next, an air sac was created subcutaneously on the dorsal side of a 6- to 8-week-old # 5781 & female female mouse, and the first chamber was transplanted.
- Compound A was orally administered, and thereafter, was administered once a day for 3 consecutive days.
- Four days after the implantation of the chamber 51 Cr-labeled mouse erythrocytes were injected into the tail vein, and one hour later, the skin in contact with the first chamber was excised under anesthesia. After freezing, only the portion in contact with the first chamber was accurately cut off, and the blood volume was measured by an a-counter. Then, a value obtained by subtracting the blood volume in the chamber not containing the cancer cells from the blood volume was defined as the amount of angiogenesis.
- the experiment was performed with 10 animals per group as a control and 5 animals per group as a compound administration group.
- T / C the amount of angiogenesis in the group administered with the compound.
- the amount of angiogenesis in the group administered with the Zvehicle x 100 was evaluated.
- Example 7 Inhibition of integrin ⁇ 2 expression on human umbilical vein vascular endothelial cells (HUVEC)
- each compound suppressed the expression of integrin ⁇ 2 on the cell surface at a concentration of 0.5 g / ml.
- the compounds according to the present invention are specifically disclosed in JP-A-7-167708 and JP-A-8-231505, and are further synthesized by Production Examples and representative compounds of the invention compounds. Examples are given below. It goes without saying that the present invention is not limited to these.
- reaction solution (80 ml) was added dropwise at 110.
- the reaction solution was added to a sulfur dioxide saturated acetic acid solution (a solution in which sulfur dioxide was saturated with 250 ml of acetic acid and 2.1 g of cuprous chloride was added) under ice-cooling and stirring.
- a sulfur dioxide saturated acetic acid solution (a solution in which sulfur dioxide was saturated with 250 ml of acetic acid and 2.1 g of cuprous chloride was added) under ice-cooling and stirring.
- the reaction solution was poured into ice water (500 mU), extracted with ethyl ether, washed successively with saturated aqueous sodium hydrogen carbonate, water and saturated saline, and dried over magnesium sulfate.
- Reduce solvent The mixture was evaporated under reduced pressure, a mixed solution of getyl ether and hexane was added to the residue, and the crystals were collected by filtration to obtain 16.0 g of the title compound.
- the organic layer was washed sequentially with a 0.1N aqueous hydrochloric acid solution, water, and saturated saline, and dried over magnesium sulfate. After concentration, the residue was purified by silica gel chromatography to obtain 6.7 g of the title compound.
- Chlorine gas was introduced into a concentrated hydrochloric acid solution (1.5 ml) of 1.3 g (5.6 mmol) of the compound of Production Example 30 under ice-cooling. After stirring for 30 minutes, the reaction solution was added to ice water, and extracted with ethyl acetate. The organic layer was washed sequentially with water and saturated saline, dried over magnesium sulfate, and concentrated. The residue was added to a solution of 1.2 g (5.35 mmol) of the compound of Production Example 22 in pyridine (6 ml), and the mixture was stirred at room temperature overnight. Water was added and extracted with ethyl acetate.
- reaction solution was added to a sulfur dioxide saturated acetic acid solution (a solution in which sulfur dioxide was saturated with 30 ml of acetic acid and 0.97 g of cupric chloride ⁇ dihydrate was added) under ice-cooling and stirring. After stirring at room temperature for 40 minutes, the reaction solution was poured into ice water to saturate sodium chloride. The mixture was extracted with ethyl acetate, dried over magnesium sulfate, and concentrated to dryness to give 1.7 g of the title compound.
- the title compound was obtained by hydrogenating 3-chloro-7-nitro-1H-indole at room temperature and normal pressure in the presence of a platinum-carbon catalyst.
- Production Example 13 210 mg (1.4 mmol) of phosphorus oxychloride was added to 0 g (14 mmol) of 3a5-bromo-3-formyl-7-nitro-1H-indole dimethylformamide (0 mmol) at 0 ° C under nitrogen atmosphere. Stir for 30 minutes. 240 mg (1.0 mmol) of the compound of Production Example 12a was added at 0 ° C, and the mixture was stirred at 0 ° C for 20 minutes and then at 100 ° C for 30 minutes. The reaction mixture was cooled with water, poured into ice water, and stirred for 30 minutes while maintaining a pH of 7 to 8 by adding a 1 N aqueous sodium hydroxide solution. The resulting precipitate is collected by filtration, washed with water, and washed. Purification by Jamaicagel column chromatography gave 239 mg of the title compound.
- 6-chloro-3-N- (1H-indole-7-yl) obtained by reacting 6-chloro-3-pyridinesulfonyl chloride with the compound of Production Example 2a in the same manner as in Example 1a-3 _ Pyridine sulfonamide was chlorinated in the same manner as in Example 2a to give the title compound.
- Melting point Partially starts to be colored black at around 220 and decomposes gradually from around 240 ° C (recrystallized from ethanol / n-hexane)
- Synthesis Example 10a Compound l.Og (3.01 mmol) was added to 4.8 ml of ethanol, and while stirring, 2.4 ml of 30% aqueous hydrogen peroxide and 360/1 of 6N sodium hydroxide aqueous solution were divided into three portions each. (At a reaction temperature of about 50). After stirring at 50 ° C for another 30 minutes, the mixture was acidified by adding dilute hydrochloric acid, and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate, concentrated, and the residue was purified by silica gel column chromatography to give the title compound (600 mg).
- Synthetic Example 4 1 a N-(3-chloro- 1H-indole 7-yl) -41- (methoxycarbonylamino) 170 mg (1.8 mmol) of methyl chloroformate was added to a pyridine solution (1 ml) of 38 mg (0.18 mmol) of the compound of Synthesis Example 3a, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography to give the title compound (20 mg).
- the title compound was obtained from 4- (1-pyrrolidinylsulfonyl) benzenesulfonyl chloride and the compound of Production Example 10a in the same manner as in Synthesis Example 1a.
- Example 33a To a solution obtained by dissolving the compound lOOmg (0.31 mmol) of Example 33a in 2 ml of glacial acetic acid under ice-cooling, 1 ml of an aqueous solution of 32 mg (0.46 mmol) of sodium nitrite was added dropwise. After stirring for 1 hour, aqueous sodium bicarbonate was added to adjust the pH to about 8, followed by stirring for 10 minutes. The mixture was extracted with ethyl acetate, washed with water, and dried over magnesium sulfate. After concentration, the residue was purified by silica gel thin layer chromatography to obtain 54 mg of the title compound.
- a mixture of 50 g (0.291 mol) of 2-bromoaniline and 63 g (0.291 mol) of ethethylethoxymethylene malonate is heated at 100 ° C. under reduced pressure for 3 hours, and further heated at 200 ° C. for 12 hours. After completion of the reaction, the solid of the reaction mixture was washed with ethyl acetate, and the crystals were collected by filtration and dried to obtain 50 g of the title compound.
- 350 mg of the amide form (ll millimolile) was added to a mixed solution of 4 ml of methanol and 2 ml of HCl, and the mixture was stirred at room temperature for 1 hour.
- the reaction solution was basified with aqueous ammonia, extracted with ethyl acetate, the organic layer was washed with brine, dried over magnesium sulfate, and concentrated to give 240 mg of the title compound.
- Tributylvinyltin (2.8 ml) and terakistrif were added to a toluene solution (20 ml) of 2.0 g (7.4 mmol) of ethyl-4,8-dichroquinoline-3-carboxylate obtained in the same manner as in Production Example 4b.
- Enylphosphine palladium (171 mg) was added, and the mixture was stirred under reflux for 2 hours. After the reaction solution was filtered through celite and concentrated, the residue was purified by silica gel chromatography to obtain 1.92 g of the title compound.
- N-Bromosuccinimide 39.2 g was added to a solution of 26.67 g (0.2 mol) of 1,2,3,4-tetrahydridoisoquinoline in methylene chloride (300 ml) under ice-cooling over 20 minutes. After stirring for 40 minutes, a 30% aqueous sodium hydroxide solution (130 ml) was added to the reaction solution. The organic layer was washed with water, extracted with 10% aqueous hydrochloric acid (200 ml), and the aqueous layer was washed with methylene chloride. The aqueous layer was made alkaline with aqueous ammonia, extracted with methylene chloride, dried over magnesium sulfate, and concentrated under reduced pressure. Distill the obtained residue (about 16 mmHg, 120 degrees) to obtain 21.5 g of the title compound as an oily substance.
- 6-Aminoisoquinoline (3.348 g, Synthesis, 733 (1975)) was dissolved in pyridine (30 ml), 4-toluenesulfonyl chloride (5.13 g ) was added, and the mixture was stirred at room temperature overnight. After adding water, the mixture was extracted with ethyl acetate, washed with saturated saline, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The crystals were recrystallized from ethanol to give the title compound (5.958 g, 85%) as pale yellow crystals.
- 6- (4-Toluenesulfonylamino) isoquinoline (3.0 g, Preparation Example 2 lb) was dissolved in chloroform (100 ml), m-chloroperbenzoic acid (2.57 g) was added under ice cooling, and the mixture was stirred at room temperature overnight. . The solvent was distilled off under reduced pressure, and the obtained crystals were washed with getyl ether, collected by filtration, and dried to obtain pale yellow crystals. This was suspended in chloroform (83 ml), phosphorus oxychloride (19 ml) was added, and the mixture was heated under reflux for 5 hours.
- 1,6-Naphthyridin-2-one (1.0 g, J. Org. Chem. 4744 (1990)) was dissolved in phosphorus oxychloride (19 ml), and the mixture was heated under reflux at 120 for 2 hours. After cooling, the solvent was distilled off under reduced pressure, made alkaline with water and potassium carbonate, extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to give the title compound as orange crystals ( 0.658 g, 58.45%).
- N- (3-nitrophenethyl) phthalimide obtained in Production Example 26b was suspended in ethanol (150 ml), hydrazine (5.7 ml) was added, and the mixture was heated under reflux for 1 hour. The reaction solution was once completely dissolved, but crystals were precipitated again. After filtration and washing with cold ethanol, the solvent was distilled off under reduced pressure to obtain the title compound (5.559 g , 99%) as a yellow oil.
- N-Acetyl-N- (3-nitrophenylene) amine (2.1 g, Production Example 28b) was dissolved in ethanol (40 ml), and iron powder (2.25 g), ammonium acetate (4.3 g), water (20 ml) ) And heated under reflux for 1.5 hours. The solid was removed by filtration, washed with ethanol, and the filtrate was partially evaporated under reduced pressure. The mixture was extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to give the title compound (1.723 g, 96%) as a yellow oil.
- 6-Ethoxycarbonylamino-1-methylisoquinoline (0.629 g, Production Example 32b) was dissolved in ethanol (20 ml), 8N aqueous sodium hydroxide solution (6.8 ml) was added, and the mixture was heated under reflux for 1.5 hours. After allowing to cool to room temperature, saturated aqueous ammonium chloride was added, extracted with ethyl acetate, washed with saturated saline, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the title compound (0.311 g , 72%) as pale yellow crystals.
- 3-Nitrophenethylamine (4.559 g, Production Example 27b) was dissolved in tetrahydrofuran (130 ml), and triethylamine (8.4 ml) and di-t-butyl dicarbonate (6.6 g) were added, followed by stirring at room temperature for 2 hours. . After evaporating the solvent under reduced pressure, add saturated saline and extract with ethyl acetate, wash with saturated brine, dry over anhydrous magnesium sulfate, evaporate the solvent under reduced pressure, and title compound as a yellow oil (8.789 g, with impurities) ) Got. The next reaction was used without further purification.
- Production Example 36 b 3- (2-t butoxycarbonylaminoethylethoxycarbonyl)
- the title compound (0.320 g) was obtained as a yellow oil in the same manner as in Production Example 29b using 3- (2-t-butoxycarbonylaminoethyl) aniline (5.521 g , Production Example 35b). The next reaction was used without further purification.
- Production Example 4 7 b 6-Ethoxycarbonylamino-1-ethylisoquinoline Using N-propynyl- (3-ethoxycarbonylaminophenethyl) amine (0.747 g, Production Example 46b), a brown crystal was obtained in the same manner as in Production Example 31b-32b. Ethoxycarbonylamino-1-ethyl 1-3,4-dihydroisoquinoline was obtained, followed by the title compound (0.516 g, 75%, 2 steps) as a yellow oil.
- the title compound was obtained as a yellow oil by a method similar to that of Production Example 26b-27b using 2- (3-nitrophenyl) propan-1-ol (1.908 g, Production Example 51b).
- Production Example 5 3b 1 Small butoxycarbonylamino-2- (3-nitrophenylyl) propaneProduction Example 5 Production using 2- (3-nitrophenyl) propylamine obtained in 2b Example 35 The reaction was carried out in the same manner as in b, and the obtained residue was purified by a silica gel column to give the title compound (2.626 g) as a yellow oil.
- the title compound (5.456 g, 50.08% in 3steps) was obtained as a yellow oil by a method similar to that of Production Example 52b-55b using 3-nitropropiophenone (10 g).
- N-Boc-1-methyl-2- (3-ethoxycarbonylaminophenyl) ethylamine (1.173 g, crude) was dissolved in ethanol (5.0 ml), hydrochloric acid (5 ml) was added, and the mixture was stirred at room temperature for 1.5 hours. Then, hydrochloric acid (2.5 ml) was added, and the mixture was stirred at room temperature for 2 hours. The solvent was distilled off under reduced pressure to obtain the title compound (1.148 g, crude) as a yellow oil. It was used for the next reaction without further purification.
- 3-Amino-8-bromoquinoline 300 mg, Production Example 5b was dissolved in pyridine (5 ml), 3-pyridinesulfonyl chloride (254 mg) was added, and the mixture was stirred at room temperature for 30 minutes. After completion of the reaction, the reaction solution was poured into a saturated saline solution, and extracted with ethyl acetate. Magnesium sulfate organic layer After drying in a shim, concentrate. The obtained crude crystals were washed with ethyl acetate and IPA to give the title compound (270 mg).
- the title compound was obtained from 5-methyl-3-pyridinesulfonyl chloride.
- the title compound was obtained from 6-chloro-3-pyridinesulfonyl chloride.
- the title compound was obtained from 5_cyano 3-pyridinepyridine sulfonyl chloride.
- the title compound was obtained from 3-pyridinesulfonyl chloride.
- Synthesis Example 1 6b 4-Cyano-N- (8-iodoquinolin-3-yl) -benzenesulfonamide In the same manner as in Synthesis Example 1b, 3-amino-8-odoquinoline (Production Example 6b) and 4 The title compound was obtained from monocyanobenzenesulfonyl chloride.
- Synthesis example 2 lb N- (8-Chloroquinolin-3-yl) -6-ethyl -3-Pyridinesulfonamide
- the title compound was obtained from 3-amino-18-chloroquinoline (Production Example 9b) and 6-ethyl-3-pyridinesulfonyl chloride in the same manner as in Synthesis Example 1b.
- Synthetic Example 2 3b N- (8-Chloroquinoline-3-yl) -benzenesulfonamide
- the title was obtained from 3-amino-8-chloroquinoline (Production Example 9b) and benzenesulfonyl chloride. The compound was obtained.
- Synthesis Example 3 2b N- (8-Methylquinoline-3-yl) -4-cyanobenzenesulfonamide As in Synthesis Example 1 lb, using 305 mg of 7-amino-2-chloro-4-methylquinoline (1.58 mmol, Production Example 16b) and 0.48 g of 4-cyanobenzenesulfonyl chloride (2.4 mmol), 358 mg of white crystals were obtained. Acetic acid (6 ml), water (2 ml) and zinc (122 mg) were added to 140 mg (0.38 mmol) of the white crystals, and the mixture was stirred at 60 degrees for 15 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Fodder In General (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/181,562 US20040018192A1 (en) | 2000-02-03 | 2001-02-01 | Integrin expression inhibitors |
EP01948941A EP1258252B1 (en) | 2000-02-03 | 2001-02-01 | Integrin expression inhibitors |
JP2001556505A JP4039856B2 (ja) | 2000-02-03 | 2001-02-01 | インテグリン発現阻害剤 |
AU28867/01A AU781506B2 (en) | 2000-02-03 | 2001-02-01 | Integrin expression inhibitors |
MXPA02007249A MXPA02007249A (es) | 2000-02-03 | 2001-02-01 | Inhibidor de la expresion de integrina. |
NZ520299A NZ520299A (en) | 2000-02-03 | 2001-02-01 | Integrin expression inhibitors containing sulphonamide derivatives |
AT01948941T ATE464892T1 (de) | 2000-02-03 | 2001-02-01 | Inhibitoren der integrinexpression |
CA2399001A CA2399001C (en) | 2000-02-03 | 2001-02-01 | Integrin expression inhibitor |
DE60141889T DE60141889D1 (de) | 2000-02-03 | 2001-02-01 | Inhibitoren der integrinexpression |
HU0300544A HUP0300544A3 (en) | 2000-02-03 | 2001-02-01 | Pharmaceutical compositions containing integrin expression inhibitors |
NO20023688A NO329158B1 (no) | 2000-02-03 | 2002-08-02 | Anvendelse av en integrinekspresjonsinhiberende forbindelse for fremstilling av et middel for forebygging, behandling eller forbedring av spesifikke sykdommer. |
US11/097,218 US7834049B2 (en) | 2000-02-03 | 2005-04-04 | Integrin expression inhibitor |
US12/797,806 US20100267754A1 (en) | 2000-02-03 | 2010-06-10 | Integrin expression inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-26080 | 2000-02-03 | ||
JP2000026080 | 2000-02-03 | ||
JP2000-402084 | 2000-12-28 | ||
JP2000402084 | 2000-12-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10181562 A-371-Of-International | 2001-02-01 | ||
US11/097,218 Continuation US7834049B2 (en) | 2000-02-03 | 2005-04-04 | Integrin expression inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001056607A1 true WO2001056607A1 (fr) | 2001-08-09 |
Family
ID=26584780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/000713 WO2001056607A1 (fr) | 2000-02-03 | 2001-02-01 | Inhibiteurs de l'expression de l'integrine |
Country Status (16)
Country | Link |
---|---|
US (3) | US20040018192A1 (ja) |
EP (1) | EP1258252B1 (ja) |
JP (1) | JP4039856B2 (ja) |
KR (1) | KR100767000B1 (ja) |
CN (1) | CN100356979C (ja) |
AT (1) | ATE464892T1 (ja) |
AU (1) | AU781506B2 (ja) |
CA (1) | CA2399001C (ja) |
DE (1) | DE60141889D1 (ja) |
ES (1) | ES2341843T3 (ja) |
HU (1) | HUP0300544A3 (ja) |
MX (1) | MXPA02007249A (ja) |
NO (1) | NO329158B1 (ja) |
NZ (1) | NZ520299A (ja) |
RU (1) | RU2240826C2 (ja) |
WO (1) | WO2001056607A1 (ja) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1074542A4 (en) * | 1999-02-26 | 2002-02-06 | Eisai Co Ltd | SULFONAMID CONTAINING INDOLDER DERIVATIVES |
WO2002066073A1 (fr) * | 2001-02-21 | 2002-08-29 | Eisai C0. Ltd. | Procede servant a analyser l'effet d'un inhibiteur d'angiogenese medie par l'inhibition de l'expression de l'integrine |
WO2002070478A1 (en) * | 2001-03-06 | 2002-09-12 | Astrazeneca Ab | Indolone derivatives having vascular-damaging activity |
WO2003022271A1 (fr) * | 2001-09-05 | 2003-03-20 | Eisai C0. Ltd. | Inhibiteur d'activation lymphocytaire et remede pour maladie auto-immune |
WO2003074045A1 (fr) * | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese |
WO2004026867A2 (en) * | 2002-09-19 | 2004-04-01 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
JP2006503060A (ja) * | 2002-09-19 | 2006-01-26 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
WO2007020936A1 (ja) * | 2005-08-17 | 2007-02-22 | Daiichi Sankyo Company, Limited | 抗真菌作用二環性複素環化合物 |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
JP2008540539A (ja) * | 2005-05-10 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャンネルの調節因子としての二環系誘導体 |
WO2009057790A1 (ja) * | 2007-11-02 | 2009-05-07 | Katayama Chemical Industries Co., Ltd. | 骨及び軟骨形成タンパク質を含有する医薬品及び医療器具 |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
JP2010536846A (ja) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 |
WO2011043359A1 (ja) | 2009-10-06 | 2011-04-14 | 協和発酵キリン株式会社 | 芳香族複素環化合物を含有する医薬 |
US7999109B2 (en) | 2002-05-24 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
JP2011190261A (ja) * | 2010-03-16 | 2011-09-29 | Purzer Pharmaceutical Co Ltd | ベンゼンスルホンアミド誘導体およびその医薬組成物 |
US8034943B2 (en) | 2005-07-11 | 2011-10-11 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
JP5094394B2 (ja) * | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
US8357699B2 (en) | 2007-01-10 | 2013-01-22 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8394826B2 (en) | 2009-05-01 | 2013-03-12 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
WO2013126608A1 (en) * | 2012-02-22 | 2013-08-29 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
US8809326B2 (en) | 2006-09-20 | 2014-08-19 | Aerie Pharmaceuticals, Inc. | Isoquinolinone Rho kinase inhibitors |
US9415043B2 (en) | 2013-03-15 | 2016-08-16 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE305302T1 (de) | 1999-12-28 | 2005-10-15 | Eisai Co Ltd | Heterozyklische verbindungen mit sulfonamid- gruppen |
GB0215650D0 (en) * | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
US7754894B2 (en) * | 2003-09-10 | 2010-07-13 | Eisai R&D Management Co., Ltd. | Crystalline sulfonamide-containing indole compound and process for preparing the same |
US20070104716A1 (en) * | 2003-11-22 | 2007-05-10 | Sloan-Kettering Institute For Cancer Research | Methods for controlling pathological angiogenesis by inhibition of a6b4 integrin |
WO2005090297A1 (en) * | 2004-03-19 | 2005-09-29 | Biotie Therapies Corporation | Sulphonamide derivatives |
RS52918B (en) | 2004-04-02 | 2014-02-28 | The Regents Of The University Of California | PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE |
WO2007008942A2 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
FI20055496A0 (fi) * | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Kollageenireseptorien alfa-l-domeeniin sitoutuvat modulaattorit |
FI20055498A0 (fi) * | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
CN102481347A (zh) | 2009-07-24 | 2012-05-30 | 加州大学董事会 | 治疗和预防整合素αvβ5相关疾病的方法及组合物 |
CN102199148A (zh) * | 2010-03-25 | 2011-09-28 | 瑞安大药厂股份有限公司 | 苯磺酰胺衍生物及其医药组合物 |
FR2984316B1 (fr) * | 2011-12-16 | 2017-08-11 | Oreal | Coupleur de structure 7-amino-indole, composition tinctoriale en comprenant, procedes et utilisations. |
CN104163798A (zh) * | 2014-07-29 | 2014-11-26 | 苏州康润医药有限公司 | 3-氨基-8-三氟甲基喹啉的合成方法 |
CN104098498A (zh) * | 2014-07-30 | 2014-10-15 | 天津市斯芬克司药物研发有限公司 | 一种吲唑类化合物及其制备方法 |
WO2016087593A1 (en) * | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
JP7150723B2 (ja) | 2016-12-14 | 2022-10-11 | ビオラ・セラピューティクス・インコーポレイテッド | 消化管疾病のインテグリン阻害薬による治療 |
AU2018386223A1 (en) * | 2017-12-14 | 2020-06-04 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders that recruit DCAFT15 |
CA3085675A1 (en) | 2017-12-15 | 2019-06-20 | Bayer Animal Health Gmbh | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives |
EP3743065A1 (en) | 2018-01-25 | 2020-12-02 | Dana-Farber Cancer Institute, Inc. | Sulfonamide derivatives for protein degradation |
WO2019246455A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
EP3873900A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
WO2022173805A1 (en) * | 2021-02-09 | 2022-08-18 | Triana Biomedicines, Inc. | Amide and ether substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereof |
US20240148744A1 (en) * | 2021-02-09 | 2024-05-09 | Celgene Corporation | Sulfonamides and their use for treatment of helminthic infections and diseases |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007276A1 (fr) * | 1993-09-10 | 1995-03-16 | Eisai Co., Ltd. | Derives bicycliques heterocycliques d'ester sulfonique et de sulfonamide |
WO1997036861A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Meta-substituted phenylene sulphonamide derivatives |
WO1997036862A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS |
WO1997036859A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
WO1998044797A1 (en) * | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
WO1998058902A1 (en) * | 1997-06-23 | 1998-12-30 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4β1MEDIATED CELL ADHESION |
WO1999035163A1 (en) * | 1998-01-08 | 1999-07-15 | Celltech Therapeutics Limited | Phenylalanine derivatives |
WO1999052493A2 (en) * | 1998-04-16 | 1999-10-21 | Texas Biotechnology Corporation | Compounds that inhibit the binding of integrins to their receptors |
WO2000032575A1 (en) * | 1998-11-30 | 2000-06-08 | Celltech Therapeutics Limited | β-ALANINE DERIVATIVES AS α4 INTEGRIN INHIBITORS |
WO2000038786A2 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
WO2000041469A2 (en) * | 1999-01-15 | 2000-07-20 | Bayer Aktiengesellschaft | β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9115160D0 (en) | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5574018A (en) | 1994-07-29 | 1996-11-12 | Amgen Inc. | Conjugates of vitamin B12 and proteins |
JP3690831B2 (ja) * | 1995-02-27 | 2005-08-31 | エーザイ株式会社 | インドール含有スルホンアミド誘導体 |
US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
AU2323897A (en) * | 1996-03-29 | 1997-10-22 | G.D. Searle & Co. | Cyclopropyl alkanoic acid derivatives |
CA2250690A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Cinnamic acid derivatives and their use as integrin antagonists |
AU6696698A (en) * | 1997-03-11 | 1998-09-29 | Allergan Sales, Inc. | Anti-angiogenic agents |
JP2003504301A (ja) * | 1998-04-01 | 2003-02-04 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | インテグリンアンタゴニスト |
JP2000247949A (ja) * | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
-
2001
- 2001-02-01 EP EP01948941A patent/EP1258252B1/en not_active Expired - Lifetime
- 2001-02-01 CA CA2399001A patent/CA2399001C/en not_active Expired - Fee Related
- 2001-02-01 CN CNB018043887A patent/CN100356979C/zh not_active Expired - Fee Related
- 2001-02-01 KR KR1020027009945A patent/KR100767000B1/ko not_active IP Right Cessation
- 2001-02-01 HU HU0300544A patent/HUP0300544A3/hu unknown
- 2001-02-01 WO PCT/JP2001/000713 patent/WO2001056607A1/ja active IP Right Grant
- 2001-02-01 NZ NZ520299A patent/NZ520299A/en not_active IP Right Cessation
- 2001-02-01 AU AU28867/01A patent/AU781506B2/en not_active Ceased
- 2001-02-01 MX MXPA02007249A patent/MXPA02007249A/es active IP Right Grant
- 2001-02-01 US US10/181,562 patent/US20040018192A1/en not_active Abandoned
- 2001-02-01 RU RU2002123580/15A patent/RU2240826C2/ru not_active IP Right Cessation
- 2001-02-01 ES ES01948941T patent/ES2341843T3/es not_active Expired - Lifetime
- 2001-02-01 JP JP2001556505A patent/JP4039856B2/ja not_active Expired - Fee Related
- 2001-02-01 DE DE60141889T patent/DE60141889D1/de not_active Expired - Lifetime
- 2001-02-01 AT AT01948941T patent/ATE464892T1/de not_active IP Right Cessation
-
2002
- 2002-08-02 NO NO20023688A patent/NO329158B1/no not_active IP Right Cessation
-
2005
- 2005-04-04 US US11/097,218 patent/US7834049B2/en not_active Expired - Fee Related
-
2010
- 2010-06-10 US US12/797,806 patent/US20100267754A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007276A1 (fr) * | 1993-09-10 | 1995-03-16 | Eisai Co., Ltd. | Derives bicycliques heterocycliques d'ester sulfonique et de sulfonamide |
WO1997036861A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Meta-substituted phenylene sulphonamide derivatives |
WO1997036862A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS |
WO1997036859A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
US5843906A (en) * | 1996-03-29 | 1998-12-01 | G. D. Searle & Co. | Meta-substituted phenylene sulphonamide derivatives |
WO1998044797A1 (en) * | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
WO1998058902A1 (en) * | 1997-06-23 | 1998-12-30 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4β1MEDIATED CELL ADHESION |
WO1999035163A1 (en) * | 1998-01-08 | 1999-07-15 | Celltech Therapeutics Limited | Phenylalanine derivatives |
WO1999052493A2 (en) * | 1998-04-16 | 1999-10-21 | Texas Biotechnology Corporation | Compounds that inhibit the binding of integrins to their receptors |
WO2000032575A1 (en) * | 1998-11-30 | 2000-06-08 | Celltech Therapeutics Limited | β-ALANINE DERIVATIVES AS α4 INTEGRIN INHIBITORS |
WO2000038786A2 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
WO2000041469A2 (en) * | 1999-01-15 | 2000-07-20 | Bayer Aktiengesellschaft | β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6469043B1 (en) | 1999-02-26 | 2002-10-22 | Eisai Co., Ltd. | Sulfonamide-containing indole compounds |
EP1074542A4 (en) * | 1999-02-26 | 2002-02-06 | Eisai Co Ltd | SULFONAMID CONTAINING INDOLDER DERIVATIVES |
US6638964B2 (en) | 1999-02-26 | 2003-10-28 | Eisai Co., Ltd. | Sulfonamide-containing indole compounds |
US6673787B2 (en) | 1999-02-26 | 2004-01-06 | Eisai Co., Ltd. | Sulfonamide-containing indole compounds |
US7122318B2 (en) | 2001-02-21 | 2006-10-17 | Eisai Co., Ltd. | Method for testing effect of angiogenesis inhibitor via integrin expression inhibition |
WO2002066073A1 (fr) * | 2001-02-21 | 2002-08-29 | Eisai C0. Ltd. | Procede servant a analyser l'effet d'un inhibiteur d'angiogenese medie par l'inhibition de l'expression de l'integrine |
WO2002070478A1 (en) * | 2001-03-06 | 2002-09-12 | Astrazeneca Ab | Indolone derivatives having vascular-damaging activity |
WO2003022271A1 (fr) * | 2001-09-05 | 2003-03-20 | Eisai C0. Ltd. | Inhibiteur d'activation lymphocytaire et remede pour maladie auto-immune |
EP1481678A1 (en) * | 2002-03-05 | 2004-12-01 | Eisai Co., Ltd. | Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor |
EP1481678A4 (en) * | 2002-03-05 | 2009-12-30 | Eisai R&D Man Co Ltd | ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR |
JPWO2003074045A1 (ja) * | 2002-03-05 | 2005-06-23 | エーザイ株式会社 | スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤 |
WO2003074045A1 (fr) * | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese |
US8030517B2 (en) | 2002-05-24 | 2011-10-04 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US7999109B2 (en) | 2002-05-24 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US9035096B2 (en) | 2002-05-24 | 2015-05-19 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
JP4845380B2 (ja) * | 2002-09-19 | 2011-12-28 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
WO2004026867A2 (en) * | 2002-09-19 | 2004-04-01 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
JP4845379B2 (ja) * | 2002-09-19 | 2011-12-28 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン |
JP2006507254A (ja) * | 2002-09-19 | 2006-03-02 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン |
US6992080B2 (en) | 2002-09-19 | 2006-01-31 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
JP2006503060A (ja) * | 2002-09-19 | 2006-01-26 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
US7452902B2 (en) | 2002-09-19 | 2008-11-18 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
WO2004026867A3 (en) * | 2002-09-19 | 2004-08-05 | Schering Corp | Imidazopyridines as cyclin dependent kinase inhibitors |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7335653B2 (en) | 2002-11-18 | 2008-02-26 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US8642808B2 (en) | 2002-11-18 | 2014-02-04 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
US10364240B2 (en) | 2002-11-18 | 2019-07-30 | ChemoCentryx. Inc. | Aryl sulfonamides |
US9890148B2 (en) | 2002-11-18 | 2018-02-13 | Chemocentryx, Inc. | Aryl sulfonamides |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US7582661B2 (en) | 2002-11-18 | 2009-09-01 | Chemocentryx, Inc. | Aryl sulfonamides |
JP5094394B2 (ja) * | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
JP2008540539A (ja) * | 2005-05-10 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャンネルの調節因子としての二環系誘導体 |
US8455647B2 (en) | 2005-07-11 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8034943B2 (en) | 2005-07-11 | 2011-10-11 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
WO2007020936A1 (ja) * | 2005-08-17 | 2007-02-22 | Daiichi Sankyo Company, Limited | 抗真菌作用二環性複素環化合物 |
US8809326B2 (en) | 2006-09-20 | 2014-08-19 | Aerie Pharmaceuticals, Inc. | Isoquinolinone Rho kinase inhibitors |
US10624882B2 (en) | 2006-09-20 | 2020-04-21 | Aerie Pharmaceuticals, Inc. | Rho kinase inhibitors |
US10472327B2 (en) | 2007-01-10 | 2019-11-12 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US9365518B2 (en) | 2007-01-10 | 2016-06-14 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10899714B2 (en) | 2007-01-10 | 2021-01-26 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8357699B2 (en) | 2007-01-10 | 2013-01-22 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8921392B2 (en) | 2007-01-10 | 2014-12-30 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US9890123B2 (en) | 2007-01-10 | 2018-02-13 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
JP2010536846A (ja) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 |
WO2009057790A1 (ja) * | 2007-11-02 | 2009-05-07 | Katayama Chemical Industries Co., Ltd. | 骨及び軟骨形成タンパク質を含有する医薬品及び医療器具 |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8871757B2 (en) | 2008-01-17 | 2014-10-28 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US10882840B2 (en) | 2008-07-25 | 2021-01-05 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US11021456B2 (en) | 2008-07-25 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US9096569B2 (en) | 2008-07-25 | 2015-08-04 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10532993B2 (en) | 2008-07-25 | 2020-01-14 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US9512101B2 (en) | 2008-07-25 | 2016-12-06 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US8759388B2 (en) | 2008-07-25 | 2014-06-24 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10112920B2 (en) | 2008-07-25 | 2018-10-30 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US9884840B2 (en) | 2008-07-25 | 2018-02-06 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US8394826B2 (en) | 2009-05-01 | 2013-03-12 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US8716310B2 (en) | 2009-05-01 | 2014-05-06 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US11618748B2 (en) | 2009-05-01 | 2023-04-04 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US9951059B2 (en) | 2009-05-01 | 2018-04-24 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10174017B2 (en) | 2009-05-01 | 2019-01-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US11028081B2 (en) | 2009-05-01 | 2021-06-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10654844B2 (en) | 2009-05-01 | 2020-05-19 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10316029B2 (en) | 2009-05-01 | 2019-06-11 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
WO2011043359A1 (ja) | 2009-10-06 | 2011-04-14 | 協和発酵キリン株式会社 | 芳香族複素環化合物を含有する医薬 |
JP2011190261A (ja) * | 2010-03-16 | 2011-09-29 | Purzer Pharmaceutical Co Ltd | ベンゼンスルホンアミド誘導体およびその医薬組成物 |
US9884826B2 (en) | 2012-02-22 | 2018-02-06 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
US10370333B2 (en) | 2012-02-22 | 2019-08-06 | Sanford-Burnham Prebys Medical Discovery Institute | Sulfonamide compounds and uses as TNAP inhibitors |
US9458147B2 (en) | 2012-02-22 | 2016-10-04 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
WO2013126608A1 (en) * | 2012-02-22 | 2013-08-29 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
JP2015508102A (ja) * | 2012-02-22 | 2015-03-16 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Tnap阻害剤としてのスルホンアミド化合物およびその使用 |
US11197853B2 (en) | 2013-03-15 | 2021-12-14 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US11185538B2 (en) | 2013-03-15 | 2021-11-30 | Aerie Pharmaceuticals, Inc. | Compositions for treating glaucoma or reducing intraocular pressure |
US10568878B2 (en) | 2013-03-15 | 2020-02-25 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9931336B2 (en) | 2013-03-15 | 2018-04-03 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9993470B2 (en) | 2013-03-15 | 2018-06-12 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9415043B2 (en) | 2013-03-15 | 2016-08-16 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US11020385B2 (en) | 2013-03-15 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US10588901B2 (en) | 2013-03-15 | 2020-03-17 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9849122B2 (en) | 2013-03-15 | 2017-12-26 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11590123B2 (en) | 2016-08-31 | 2023-02-28 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11707460B2 (en) | 2016-08-31 | 2023-07-25 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11312700B2 (en) | 2017-03-31 | 2022-04-26 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US12018012B2 (en) | 2017-03-31 | 2024-06-25 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11891376B2 (en) | 2018-09-14 | 2024-02-06 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Also Published As
Publication number | Publication date |
---|---|
US7834049B2 (en) | 2010-11-16 |
RU2002123580A (ru) | 2004-03-20 |
KR100767000B1 (ko) | 2007-10-15 |
EP1258252B1 (en) | 2010-04-21 |
US20050176712A1 (en) | 2005-08-11 |
JP4039856B2 (ja) | 2008-01-30 |
CA2399001A1 (en) | 2001-08-09 |
EP1258252A4 (en) | 2005-11-02 |
AU781506B2 (en) | 2005-05-26 |
HUP0300544A2 (hu) | 2003-07-28 |
NO329158B1 (no) | 2010-08-30 |
CA2399001C (en) | 2010-07-20 |
ES2341843T3 (es) | 2010-06-29 |
HUP0300544A3 (en) | 2005-03-29 |
US20040018192A1 (en) | 2004-01-29 |
NZ520299A (en) | 2004-05-28 |
NO20023688D0 (no) | 2002-08-02 |
NO20023688L (no) | 2002-10-03 |
CN1396833A (zh) | 2003-02-12 |
EP1258252A1 (en) | 2002-11-20 |
ATE464892T1 (de) | 2010-05-15 |
MXPA02007249A (es) | 2002-12-09 |
DE60141889D1 (de) | 2010-06-02 |
AU2886701A (en) | 2001-08-14 |
CN100356979C (zh) | 2007-12-26 |
KR20020073575A (ko) | 2002-09-27 |
US20100267754A1 (en) | 2010-10-21 |
RU2240826C2 (ru) | 2004-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001056607A1 (fr) | Inhibiteurs de l'expression de l'integrine | |
JP3545461B2 (ja) | 二環式ヘテロ環含有スルホンアミド誘導体 | |
RU2128648C1 (ru) | Производные сульфонамида, способы их получения, фармацевтическая композиция и способ лечения | |
JP4234344B2 (ja) | スルホンアミド含有複素環化合物 | |
US6403588B1 (en) | Imidazopyridine derivatives | |
JP3863722B2 (ja) | 化合物 | |
WO2006080450A1 (ja) | Igf-1r阻害剤 | |
HU228979B1 (en) | Pyrrole substituted 2-indolinone protein kinase inhibitors | |
HUT71553A (en) | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties | |
JP2008526702A (ja) | 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用 | |
JPH08507067A (ja) | Hiv逆転写酵素阻害剤 | |
JP4007743B2 (ja) | 血管新生阻害剤 | |
JP2008514572A (ja) | 可溶性アデニル酸シクラーゼのインヒビターとしてのインドール誘導体 | |
EP4066895A1 (en) | Compound having lysophosphatidic acid receptor agonistic activity and pharmaceutical use of said compound | |
KR100767002B1 (ko) | 인테그린 발현 저해제 | |
AU2022292903A1 (en) | 3-substituted 1h-pyrrolo[2,3-b]pyridine as grk5 modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN HU JP KR MX NO NZ RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 556505 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 28867/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10181562 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 520299 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001948941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/007249 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2399001 Country of ref document: CA Ref document number: 018043887 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027009945 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: RU Ref document number: 2002 2002123580 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027009945 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001948941 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 520299 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 520299 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 28867/01 Country of ref document: AU |